Tolerability of HIV integrase inhibitors

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 422-428

  Lee, Frederick J ^a   Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

dolutegravir; elvitegravir; HIV infection; integrase; integrase inhibitors; myopathy; raltegravir

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ATAZANAVIR; COBICISTAT; CREATININE; CYTOCHROME P450 3A4; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR;

ANTIVIRAL THERAPY; BONE DENSITY; CANCER INCIDENCE; CENTRAL NERVOUS SYSTEM DISEASE; COMBINATION ANTIRETROVIRAL THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; LIPID METABOLISM; MENTAL DISEASE; NAUSEA; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TABLET; TREATMENT DURATION;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG TOXICITY; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; KIDNEY; LIPID METABOLISM; PYRROLIDINONES; QUINOLONES;

EID: 84865623088     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356682a     Document Type: Review

References (48)

1. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs 2006; 15:1507-1522.
2. Serrao E, Odde S, Ramkumar K, et al. Raltegravir, elvitegravir, and metoogravir: The birth of 'me-too' HIV-1 integrase inhibitors. Retrovirology 2009;6:25.
3. Rosemond MJ St John-Williams L Yamaguchi T et al. Enzymology of a Carbonyl Reduction Clearance Pathway For The HIV Integrase Inhibitor S-1360 Role Of Human Liver Cytosolic Aldo-keto Reductases. Chem Biol Interact 2004; 147129-139.
4. Little S, Drusano G, Schooley R. Antiviral effect of L-000870810, a novel HIV- 1 integrase inhibitor, in HIV-1 infected patients [abstract 161]. In: Abstracts ofthe 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston, Massachusetts, USA.
5. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:350-356.
6. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet2007; 369:1261-1269.
7. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of theBENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50:605-612.
8. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83:293-299.
9. Connelly S. Raltegravir NDA 22-145. U.S. Food and Drug Administration Division of Antiviral Products Antiviral Drugs Advisory Committee Medical Review. FDA; 2007, pp. 45-111.
10. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients withHIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
11. FDA Isentress Prescribing Information. 2012, 1-18 [updated March 28].
12. Perez-Matute P, Perez-Martinez L, Blanco JR, et al. Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res 2011; 9:174-179.
13. Minami R, Yamamoto M, Takahama S, et al. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: The minimal effect of raltegravir and atazanavir. J Infect Chemother 2011; 17:183-188
14. Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 2012; 26:475-481
15. Kawaguchi I IT, Ishibashi M, Irie S, Kakee A. Safety and pharmacokinetics of single oral dose of JTK 303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers [abstract 580]. In: Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 5-9 February 2006; Denver, Colorado, USA.
16. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43:1-5.
17. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87:322-329.
18. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxilfumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumaratefor the initial treatment of HIV infection. AIDS 2011; 25:F7-F12.
19. DeJesus E, Rockstroh J, Henry K et al. Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate with atazanavir/ritonavir-boosted plus emtricitabine/ tenofovir disoproxil fumarate in treatment naive HIV-1 subjects showing efficacy,safety, and pharmacokinetics [abstract 627]. In: Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March2012; Seattle, Washington, USA.Phase 3 study of elvitegravir demonstrates the variable effect upon lipid profilecompared with boosted atazanavir in the presence of boosting with cobicistat.
20. Sax P, DeJesus E, Mills A et al. Elvitegravir/cobicistat/emtricitabine/ tenofovir (Quad) has noninferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naive HIV-1 subjects [abstract 101]. In: Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections;5-8 March 2012; Seattle, Washington, USA. Phase 3 study of elvitegravir demonstrates the variable effect upon lipid profilecompared with efavirenz in the presence of boosting with cobicistat.
21. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011; 25:1881-1886.
22. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: Results of a phase 2, randomized,controlled, dose-ranging clinical trial. J Infect Dis 2010; 201:814-822.
23. Lepist EI MB, Tong L, Roy A, et al. Effect of cobicistat and ritonavir on proximalrenal tubular cell uptake and efflux transporters [abstract A1-1724]. In:Abstracts of the 51st Interscience Conference on Antimicrobial Agentsand Chemotherapy (ICAAC 2011); 17-20 September 2011; Chicago,Illinois, USA.This study describes the likely mechanism of cobicistat-induced inhibition ofproximal renal tubular secretion of creatinine.
24. Min S, Carrod A, Curtis L et al. Safety profile of dolutegravir (DTG, S/GSK1349572), in combination with other antiretrovirals in antiretroviral (ART)-naíve and ART-experienced adults from two phase IIb studies [abstract TUPE238]. In: Abstracts of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy.
25. Eron JE, Durant J, Poizot-Martin I et al. Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: Initial results of VIKING study (ING112961) [Abstract MOAB0105]. In: Abstracts of the XVIII International AIDS Conference; 18-23 July 2010; Vienna, Austria.
26. Eron JE, Kumar PN, Lazzarin A et al. DTG in Subjects with HIV Exhibiting RAL Resistance: Functional Monotherapy Results of VIKING Study Cohort II [Abstract 151LB]. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, Massachusetts, USA.
27. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111-118
28. GlaxoSmithKline. A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects (ING111207). 2008.
29. GlaxoSmithKline. An Open Label, Non-Randomized, Single dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853). 2009.
30. GlaxoSmithKline. A randomized, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of a supratherapeutic dose of GSK1349572 250 mg and a randomized, open-label study to evaluate the effects of omeprazole 40 mg daily and a high fat meal on the pharmacokinetics of GSK1349572 50mg in healthy adult subjects (ING112941). 2009.
31. GlaxoSmithKline. A Study to Evaluate the Effect of a Single 250mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856). 2009.
32. GlaxoSmithKline. Phase I, Open Label, Randomized, Drug-Drug Interaction Study in Healthy Subjects to Investigate the Effects of Co-administered Atazanavir/Ritonavir (300mg/100mg) or Atazanavir 400mg Administered Once Daily on the Steady-State Plasma Pharmacokinetics of GSK1349572 30mg Administered Once Daily (ING111854). 2009.
33. GlaxoSmithKline. A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects (ING113097). 2011.
34. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1- infected adults. AIDS 2011; 25:1737-1745.
35. Koteff J, Borland J, Chen S et al. An open label, placebo-controlled study to evaluate the effect of dolutegravir (DTG, S/GSK1349572) on iohexol and para-aminohippurate clearance in healthy subjects [Abstract A1-1728]. In: Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2011; Chicago, Illinois, USA. This study describes the effect of dolutegravir on renal function, and likely mechanisms involving proximal tubular clearance of creatinine.
36. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: Results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-
37. Reynes J, Lawal A, Pulido F, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: The progress study, 48-week results. HIV Clin Trials 2011; 12:255-267.
38. Gallien S, Braun J, Delaugerre C, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtidebased regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011; 66:2099-2106.
39. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 noninferiority trial. Lancet Infect Dis 2011; 11:907-915.
40. Young B, Vanig T, Dejesus E, et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naive HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials 2010; 11:260-269.
41. Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008; 22:1382-1384.
42. Dori L, Buonomini AR, Viscione M, et al. A case of rhabdomyolysis associated with raltegravir use. AIDS 2010; 24:473-475.
43. Masia M, Enriquez R, Sirvent A, et al. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect 2010; 61:189-190.
44. Croce F, Vitello P, Dalla Pria A, et al. Severe raltegravir-associated rhabdomyolysis: A case report and review of the literature. Int J STD AIDS 2010; 21:783-785.
45. Madeddu G, Soddu V, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from a multicenter study. J Int AIDS Soc 2010; 13:111.
46. Falconer M. Rosuvastatin NDA 21-366. U.S. Food and Drug Administration Center for Drug Evaluation and Research Clinical Review. FDA; 2009, pp. 13-38.
47. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Proceedings of the guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, Maryland, USA: Department of Health and Human Services; 2012.
48. Molina J, LaMarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, doubleblind, phase 3, noninferiority study. Lancet Infect Dis 2012; 12:27-35.